Lupin Ltd (LUPIN) — shareholding pattern, promoter holding, financials and share price
About Lupin Ltd (LUPIN)
Lupin Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as LUPIN and on the BSE under scrip code 500257. Its ISIN is INE326A01037.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
Lupin is a global, innovation-led pharmaceutical company that develops and markets branded and generic formulations, biosimilars, injectables, inhalation products and APIs across 100+ countries, with particular strength in cardiovascular, diabetology, respiratory and anti-TB. The company combines a large India commercial footprint with a growing regulated-market presence in the United States and other developed markets.
Q3 FY26 was a company record: consolidated sales of INR 71,005 million (↑26% YoY), EBITDA of INR 22,095 million (↑62% YoY) with a 31.1% margin, and net income of INR 11,756 million (↑38% YoY); Lupin highlighted broad-based regional growth led by a USD 350 million quarter in the US, driven by Tolvaptan, Mirabegron and new product momentum.
Listed peers in Pharmaceuticals: Cipla Ltd, Zydus Lifesciences Ltd, Mankind Pharma Ltd, Dr Reddys Laboratories Ltd, Aurobindo Pharma Ltd, Laurus Labs Ltd.
Valuation & Returns
10 Jul 2026At ₹2,496.9 a share on 10 Jul 2026, Lupin Ltd (LUPIN) was valued at a price-to-earnings ratio of 21.32x against an industry P/E of 36.41x and a price-to-book of 6.64x on a book value of ₹376.25 per share as of Mar 2025. Solomo computes return on equity of 31.13% and return on capital employed of 32.26% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 21.32x
- Industry P/E
- 36.41x
- P/B
- 6.64x
- EPS (TTM)
- ₹117.13
- Book value / share
- ₹376.25
- ROE
- 31.13%
- ROCE
- 32.26%
- ROA
- 18.34%
- Debt / equity
- 0.32x
- Dividend yield
- 0.48%
- EBITDA margin
- 31.59%
- 52-week range
- ₹1,838.65 – ₹2,526
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Lupin Ltd (LUPIN) reported revenue of ₹27,958 crore, net profit of ₹5,355 crore and earnings per share of ₹116.65. That compares with revenue of ₹22,708 crore and net profit of ₹3,306 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹7,475 crore and net profit ₹1,469 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 16,405 | 16,642 | 20,011 | 22,708 | 27,958 |
| Net profit (₹ cr) | -1,528 | 448 | 1,936 | 3,306 | 5,355 |
| EPS (₹) | -33.62 | 9.45 | 42.01 | 71.88 | 116.65 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 4.58% | 9.00% | 12.96% | 13.48% |
| Profit growth | 3.84% | 40.43% | - | 70.82% |
| Stock price CAGR | 4% | 16% | 39% | 30% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 46.85% of Lupin Ltd (LUPIN) (down 0.01 pp QoQ), foreign institutional investors (FII) hold 22.42% and domestic institutional investors (DII) hold 24.65%. Market capitalisation was ₹1,14,166 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: Hdfc Trustee Company Ltd. A/C Hdfc Balanced Advantage Fund 4.37%, Life Insurance Corporation Of India 4.09%, Nps Trust- A/C Hdfc Pension Fund Management Limited Scheme E - Tier I 2.75%, Nippon Life India Trustee Ltd- A/C Nippon India Growth Mid Cap Fund 2.6%, Sbi Elss Tax Saver Fund 1.96%, Mirae Asset Large & Midcap Fund 1.74%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 46.85% | - | 22.42% | 24.65% | 53.15% |
| Mar 2026 | 46.86% | - | 21.71% | 25.32% | 53.14% |
| Dec 2025 | 46.89% | - | 21.49% | 25.58% | 53.11% |
| Sep 2025 | 46.9% | - | 20.49% | 26.55% | 53.1% |
| Jun 2025 | 46.9% | - | 21.25% | 25.56% | 53.1% |
| Mar 2025 | 46.92% | - | 21.46% | 25.41% | 53.08% |
| Dec 2024 | 46.95% | - | 22.04% | 24.74% | 53.05% |
| Sep 2024 | 46.96% | - | 21.5% | 25.09% | 53.04% |